Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIRPG Antisense RNA 1 (SIRPG-AS1)
- Target
- SIRPG-AS1
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
SIRPG Antisense RNA 1 (SIRPG-AS1) is a long non-coding RNA gene transcribed antisense to the SIRPG locus. It is currently classified as a lncRNA, with limited understanding of its specific molecular function, biological roles, or disease mechanisms. The only reported disease association is Glioma Susceptibility 1. Like other antisense RNAs, SIRPG-AS1 might participate in gene expression regulation at the transcriptional or epigenetic level, but no experimental data are presently published regarding its detailed function, molecular partners, or relevance as a therapeutic or biomarker target.
- Other names
- SIRPG-AS1SIRPG Antisense RNA 1HGNC:51229NCBI Gene:101929010Ensembl:ENSG00000237914
02
Mechanism of action
Not applicable (no drugs reported to target SIRPG-AS1; general lncRNA mechanisms involve gene expression modulation and epigenetic regulation)
03
Biological functions
Unknown (no direct data on biological functions; general lncRNAs participate in gene regulation)Antisense RNA genes are commonly implicated in transcriptional and epigenetic regulation; specific mechanisms for SIRPG-AS1 are undetermined
04
Disease associations
Glioma susceptibility (as reported "[Associated with Glioma Susceptibility 1]")Other roles not established; data on cancer, inflammation, or other disease connections are lacking for SIRPG-AS1 specifically
05
Safety considerations
Not applicable (no reports of safety concerns or therapeutic challenges relating to SIRPG-AS1)
06
Biomarkers
None reported for patient selection or efficacy monitoring (may have potential as a biomarker if future research links expression to disease susceptibility)
Beyond the preview
Go deeper on SIRPG Antisense RNA 1 (SIRPG-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIRPG Antisense RNA 1 (SIRPG-AS1).